Dapagliflozin is a potent, reversible, and highly selective SGLT2 inhibitor utilized to manage glycemic loads through a renal-centric pathway. By actively preventing glucose reabsorption in the SGLT2 channels of the nephron's proximal convoluted tubule, it promotes the direct urinary elimination of roughly 70 grams of glucose per day. This insulin-independent process aids in reducing HbA1c levels, supports steady caloric loss through glucose wasting, and provides gentle osmotic diuresis to reduce overall vascular strain.